Gradin K, Pettersson A, Hedner T, Persson B
J Neural Transm. 1985;62(3-4):305-19. doi: 10.1007/BF01252244.
8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) is a new serotonin (5-HT) receptor agonist that binds selectively to the 5-HT1A binding site. In the present paper we investigated the cardiovascular effects of 8-OH-DPAT in the normotensive Sprague-Dawley rat and in the spontaneously hypertensive rat. The acute i.v. administration of 8-OH-DPAT (5-150 micrograms/kg) was in both rat strains associated with a biphasic blood pressure response and a bradycardia. The initial pressor response was due to a direct vascular effect of 8-OH-DPAT involving activation of alpha-adrenoceptors since it was present in pithed rats and in reserpine pretreated rats and since it was attenuated by prazosin. The longer lasting hypotension was not due to a direct vascular relaxation or a presynaptic inhibition of transmitter release since the hypotension was not evident in pithed rats and since 8-OH-DPAT did not influence the pressor responses to electrical stimulation in pithed rats. Rather, the combination of hypotension and bradycardia would suggest a central site of action although the intracerebroventricular (lat. ventricles) route of administration was not more efficient (to induce hypotension) than i.v. administration. At least the bradycardia was mediated by changes in vagal as well as sympathetic discharge since it was prevented by pretreatment with atropine and propranolol in combination but not by pretreatment with either agent alone. The cardiovascular effects of 8-OH-DPAT were not prevented by pretreatment with methergoline, methiothepin, pirenperone or cianserine or by 5-HT depletion by means of p-chlorophenylalanine, which suggests that the putative 5-HT receptor that is responsible for the hypotension and bradycardia to 8-OH-DPAT is not of a presynaptic type and does not have the pharmacological characteristics of a general 5-HT1 receptor.
8-羟基-2-(二正丙基氨基)四氢萘(8-OH-DPAT)是一种新型的血清素(5-羟色胺,5-HT)受体激动剂,它能选择性地与5-HT1A结合位点相结合。在本文中,我们研究了8-OH-DPAT对正常血压的斯普拉格-道利大鼠和自发性高血压大鼠的心血管作用。静脉内急性注射8-OH-DPAT(5-150微克/千克),在这两种大鼠品系中均会引起双相血压反应和心动过缓。最初的升压反应是由于8-OH-DPAT的直接血管效应,涉及α-肾上腺素能受体的激活,因为在脊髓切断的大鼠和利血平预处理的大鼠中均存在该反应,且该反应可被哌唑嗪减弱。持续时间较长的低血压并非由于直接的血管舒张或对递质释放的突触前抑制,因为在脊髓切断的大鼠中低血压并不明显,且8-OH-DPAT不影响脊髓切断大鼠对电刺激的升压反应。相反,低血压和心动过缓的组合提示其作用位点在中枢,尽管脑室内(侧脑室)给药途径诱导低血压的效果并不比静脉内给药更有效。至少心动过缓是由迷走神经以及交感神经放电的变化介导的,因为联合使用阿托品和普萘洛尔预处理可预防心动过缓,但单独使用任何一种药物预处理均不能预防。用麦角新碱、甲硫噻平、匹仑哌隆或西潘色林预处理,或通过对氯苯丙氨酸耗竭5-HT,均不能预防8-OH-DPAT的心血管效应,这表明导致对8-OH-DPAT产生低血压和心动过缓的假定5-HT受体不是突触前型,也不具有一般5-HT1受体的药理学特征。